The numbers, attributed to their studies
Thymosin Alpha-1 Dosage as Reported in the Research Literature
What was given, to whom, by what route — logged as research data, never as instruction.
Start here
This page reports Thymosin Alpha-1 dosage exactly as it appears in the published trials — and nothing more. It is not a how-to and not a recommendation; you will not find a "take this much" line anywhere on it, because that line would be medical advice, and this is a literature digest. What you will find is what researchers actually administered: which amount, to which group of patients, by which route, for how long. Almost everything was given as a subcutaneous injection (a shot under the skin). The most-studied regimen, used in long-term hepatitis, is a small twice-weekly dose. Sepsis trials gave it more often for about a week. Below those numbers sits the pharmacology — how fast the peptide peaks and clears — which explains why the dosing schedules look the way they do. Read it as a record of the science, not as a plan.
Thymosin alpha 1 dosage
Across four decades of literature, the studied thymosin alpha 1 dosage clusters tightly. A comprehensive review reports single subcutaneous doses ranging from 0.8-6.4 mg, with multiple-dose regimens of 1.6-16 mg over five to seven days [4]. The most common chronic regimen — the hepatitis B and C standard — is 1.6 mg subcutaneous twice weekly [9]. These are reported here strictly as study-attributed research data: amounts administered to defined patient populations by a defined route, not figures for anyone to act on.
How it was dosed across the trials
The regimens track the indication. In the ETASS and TESTS sepsis trials the peptide was studied at 1.6 mg subcutaneous every 12 hours for five to seven days in adult ICU patients [2][3]. COVID-19 cohort work used 1.6 mg subcutaneous daily [6]. A severe-pancreatitis pilot studied 3.2 mg subcutaneous twice daily for 7 days, and a non-small-cell lung cancer chemoradiotherapy-adjunct study used weekly subcutaneous injection for up to twelve months [4]. Each of these is an amount given to a specific studied population by the subcutaneous route — recorded, not endorsed, and not transferable to any unstudied use.
Pharmacokinetics — why the schedule looks like this
The dosing rhythm follows the pharmacology. After subcutaneous injection in human volunteers, Thymosin Alpha-1 shows an elimination half-life of about 2 hours, with time-to-peak around 1-2 hours, peak concentration of 30-80 mcg/L, and a volume of distribution (~30-40 L) consistent with extracellular-fluid distribution; blood levels return toward baseline within about 24 hours [8]. It is highly acidic (isoelectric point near 4.2), does not bind plasma proteins extensively, and is degraded by tissue and circulating aminopeptidases — which is exactly why the therapeutic effect outlasts the brief plasma presence and why intermittent dosing is feasible despite the short half-life [8]. It is supplied lyophilized, and the essential N-terminal acetylation must be preserved for activity.
Routes studied
The subcutaneous injection is the primary clinical route in essentially every trial [4]. Mechanistic work has used in-vitro and ex-vivo systems, and preclinical studies have used in-vivo murine models (including the intraperitoneal route) [5][10]. There is no established oral, intranasal, or transdermal route in the human clinical record — the studied evidence is a subcutaneous-injection record, and that is how it is reported here.